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Summary We encountered a case of hypothyroidism showing Brugada-type electrocardiogram
(ECG). A 52-year-old man was referred to our hospital in August 2009. Past medical history
showed that liver dysfunction and face edema of unknown origin had been pointed out 1 year
earlier. He was diagnosed with primary hypothyroidism at this admission. ECG exhibited ﬁrst-
degree atrio-ventricular block (0.24 s) and showed Brugada-type ST-segment elevation ≥2mm
followed by a negative T wave (coved type) in the V1, V2 leads. On genetic analysis, the patient
demonstrated three common variants in the SCN5A gene, L1988R (c.5963 T>G), H558R (c.1673
A>G), and R1193Q (c.3578 G>A).Brugada-type ECG disappeared when the thyroid function normalized. We hypothesize that
Brugada-type ECG in hypothyroidism is modiﬁed not only by a direct effect of thyroid hormone,
but also due to SCN5A variants.
Some SCN5A gene polymorphisms or mutations will induce changes on ECG when ion channels
ism.
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Introduction
Brugada syndrome is an inherited disorder characterized by
ST-segment elevation in V1, V2 leads and increased suscep-
tibility to ventricular arrhythmias and sudden cardiac death.
We encountered a case of hypothyroidism with Brugada-
type electrocardiogram (ECG). Genetic examination showed
three common variants in SCN5A gene.
∗ Corresponding author. Tel.: +81 0238 22 2450;
fax: +81 0238 22 2876.
E-mail address: ktaira@skyblue.ocn.ne.jp (K. Taira).
r
s
c
d
2
e
o
6
1
1878-5409/$ — see front matter © 2010 Japanese College of Cardiology.
doi:10.1016/j.jccase.2010.05.011diology. Published by Elsevier Ireland Ltd. All rights reserved.
ase report
52-year-old man with diarrhea and cold sweating was
eferred to our hospital in August 2009. Medical history
howed that face edema was noted in June 2008. Mild peri-
ardial effusion and left ventricular hypertrophy were then
etected by echocardiography. He had been advised to take
0mg furosemide, when he became concerned about his
dema. He did not have a family history of sudden death
r attacks of syncope or palpitation.
On admission in August 2009, height was 177 cm, weight
5 kg, and body temperature 36.5 ◦C. Blood pressure was
10/84mmHg and pulse rate 46min−1 with regular rhythm.
Published by Elsevier Ireland Ltd. All rights reserved.
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nongenomic mechanisms [2]. However, there is no evidenceigure 1 Electrocardiogram and signal-averaged electrocard
erminal 40ms in the ﬁltered QRS complex; LAS(40), duration of
QRS, duration of the ﬁltered QRS.
is voice was deep and husky, myxo-edematous face and
ilateral legs were observed. Aurantiasis cutis was noted in
he hands. The thyroid gland was not palpable. Lambert sign
as observed in the Achilles’ tendon.
On laboratory examination white blood cell count was
290/l, red blood cell count 375× 104/l, aspartate
ransaminase (AST) 51 IU/L, alanine transaminase (ALT)
2 IU/L, lactate dehydrogenase (LDH) 354 IU/L, creatine
inase (CK) 1299 IU/L, total cholesterol 295mg/dl, thyroid
timulating hormone (TSH) >100IU/L, free T3 0.99 pg/ml,
ree T4 0.5mg/dl, TSH stimulating antibody (TSAB) 785%,
nti thyroglobulin antibody 11.5 U/ml and TSH receptor anti-
ody 8.1%. Technetium-99m uptake in the thyroid gland was
ery low (0.22%). We diagnosed the patient as having pri-
ary hypothyroidism.
ECG exhibited sinus rhythm, right axis deviation with
rst-degree atrio-ventricular block (0.24 s) and showed
rugada-type ST-segment elevation of ≥2mm followed by
negative T wave (coved type) in V1, V2 leads. The signal-
veraged ECG (GE MAC5500, Waukesha, WI, USA) showed a
ositive value for the late potential. (Duration of low ampli-
ude signals <40V in the terminal ﬁltered QRS complex,
2ms; root mean square voltage of the terminal 40ms in
he ﬁltered QRS complex, 14V) (Fig. 1).
The cardio-thoracic ratio was 54.6% on chest X-ray.
rans-thoracic echocardiography showed left ventricular
ypertrophy (posterior wall of the left ventricle 12.5mm,
nter-ventricular septum 12.5mm), and mild pericardial
ffusion. Compared with the ﬁndings on examination in July
008, the volume of pericardial effusion had not changed
ut the ejection fraction had decreased from 74% to 67%.
The patient gave informed consent for genetic anal-
sis, and demonstrated three common variants in the
i
c
c
ram on admission. RMS(40), root mean square voltage of the
amplitude signals <40V in the terminal ﬁltered QRS complex;
CN5A gene, L1988R (c.5963 T>G), H558R (c.1673 A>G), and
1193Q (c.3578 G>A), which are identiﬁed in more than 1%
f normal subjects.
After administration of levothyroxine sodium, thyroid
nd liver function improved over 2 months. ST-segment ele-
ation of ECG and pericardial effusion also disappeared
fter 2 months of medication (Fig. 2). After 7 months of
edication, the ECG changed again to Brugada-type, fol-
owing administration of the classic anti-arrhythmic drug,
ilsicainide (Fig. 3).
iscussion
e present a case report of Brugada-type ECG in a patient
ith hypothyroidism. We conjecture that the patient was
lready suffering from hypothyroidism in June 2008, judging
rom ECG or echocardiogram. The ﬁrst report of Brugada-
ype ECG with hypothyroidism was published in 2008 [1]. The
eculiar waveform disappeared with the normalization of
hyroid function, the same as in our case. Although they did
ot perform genetic analysis in their patient, they suggested
hat changes in thyroid hormone had affected the ECG due
o effects on myocardial ion channels.
The cause of the Brugada-type ECG is regarded to be a
ecrease in INa and relative increase in Ito. Thyroid hormone
ffects the action potential duration and repolarization
urrents in cardiac myocytes through both genomic andndicating that an alteration in INa current is caused by
hanges in thyroid hormone states. Voltage-gated potassium
hannels (Kv1.5, Kv4.2, Kv4.3) are also under T3 genomic
egulation. Since the Kv4.2/4.3 genes and the Kv1.4 gene
Brugada-type electrocardiogram affected by thyroid function e149
Figure 2 Clinical course. AST, aspartate transaminase; ALT, alanine transaminase; LDH, lactate dehydrogenase; GTP, -glutamyl
transpeptidase; CK, creatine kinase; TSH, thyroid stimulating hormone.
ype a
n
n
gFigure 3 The electrocardiogram changed again to Brugada t
cainide.
encode components that are required for the fast and
slow inactivation of Ito, respectively, it is possible that thy-
roid function inﬂuenced Ito through the genomic pathway.
Another route would be via the extra-nuclear nongenomic
effects of thyroid hormone on cardiac myocytes. These
effects of T3 can occur rapidly, inducing changes in various
membrane ion channels for sodium, potassium, and calcium
[1,2]. However, most patients with hypothyroidism do not
demonstrate Brugada-type ECG. Therefore, these data are
p
g
r
tfter administration of the class Ic anti-arrhythmic drug, pilsi-
ot sufﬁcient to explain Brugada-type ECG by genomic or
ongenomic thyroid function.
Some SCN5A missense mutations in the sodium-channel
ene were ﬁrst identiﬁed by Priori et al. [3] in a group of
atients with Brugada syndrome. In that paper, however,
enetic analysis in the SCN5A gene could not demonstrate a
elation to risk stratiﬁcation.
Poelzing et al. [4] reported that the R282H-SCN5A muta-
ion does not produce signiﬁcant whole-cell sodium current
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338—44.
[8] Kawaguchi T, Nomura M, Tsujikawa T, Nakaya Y, Ito S.150
nd coexistence of the common H558R-SCN5A polymor-
hism with R282H-SCN5A mutation produces fully functional
odium currents. It is suggested that this common H558R-
CN5A polymorphism rescues a genetic characteristic among
atients demonstrating Brugada syndrome with R282H-
CN5A mutation. On ECG, the common variant H558R G
llele carrier had a shorter QRS duration and lower J point
han the wild type of H558R genotype carrier with Brugada
yndrome [5]. Deschênes et al. found that the R1432G-
CN5A mutation in a patient with Brugada syndrome showed
bolition of sodium-channel expression using the patch
lamp technique [6].
It currently remains unclear what selective mutation in
he SCN5A gene causes the change to a Brugada-type ECG.
Recently, Bezzina et al. [7] reported that an ethnic-
peciﬁc haplotype variant of SCN5A promoter modulates PR
nd QRS duration. They demonstrated that genetic variation
s a key mediator of the variable effects of a sodium-channel
locker.
Alterable Brugada-type ECG can be seen under various
onditions such as sodium-channel blocker administration or
yocardial autonomic nervous dysfunction [8]. We suggest
hat these parameters may unmask the typical Brugada-type
CG in patients with some silent gene variants.
In our case, there were three common variants in the
xon of the SCN5A gene. Brugada-type ECG was observed
hen only thyroid function became low. We hypothesize
hat these three common variants may have modiﬁed the
rugada-type ECG under the hypothyroid condition in the
resent patient.
Some SCN5A gene variations will induce changes on ECG
hen the ion channels are affected by hypothyroidism.
Further research is needed to fully understand the mech-
nism.K. Taira et al.
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